138 related articles for article (PubMed ID: 22264038)
1. Characterization of the interface of the bone marrow stromal cell antigen 2-Vpu protein complex via computational chemistry.
Zhou J; Zhang Z; Mi Z; Wang X; Zhang Q; Li X; Liang C; Cen S
Biochemistry; 2012 Feb; 51(6):1288-96. PubMed ID: 22264038
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel key amino acids at the interface of the transmembrane domains of human BST-2 and HIV-1 Vpu.
Pang X; Hu S; Li J; Xu F; Mei S; Zhou J; Cen S; Jin Q; Guo F
Retrovirology; 2013 Aug; 10():84. PubMed ID: 23919512
[TBL] [Abstract][Full Text] [Related]
3. High-throughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2.
Zhang Q; Liu Z; Mi Z; Li X; Jia P; Zhou J; Yin X; You X; Yu L; Guo F; Ma J; Liang C; Cen S
Antiviral Res; 2011 Sep; 91(3):321-9. PubMed ID: 21777622
[TBL] [Abstract][Full Text] [Related]
4. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
Fritz JV; Tibroni N; Keppler OT; Fackler OT
Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
[TBL] [Abstract][Full Text] [Related]
6. Purification of eukaryotic tetherin/Vpu proteins and detection of their interaction by ELISA.
Lv M; Zhu Y; Wang J; Zhang H; Wang X; Zuo T; Liu D; Zhang J; Wu J; Kong W; Yu X
Protein Expr Purif; 2013 Oct; 91(2):112-8. PubMed ID: 23916489
[TBL] [Abstract][Full Text] [Related]
7. [Establishment of a high-throughput screening assay for interaction inhibitor between BST-2 and Vpu].
Pang XJ; Hu SQ; Zhang Y; Cen S; Jin Q; Guo F
Bing Du Xue Bao; 2012 Nov; 28(6):633-8. PubMed ID: 23367562
[TBL] [Abstract][Full Text] [Related]
8. A novel peptide to disrupt the interaction of BST-2 and Vpu.
Mi Z; Wang X; He Y; Li X; Ding J; Liu H; Zhou J; Cen S
Biopolymers; 2014 May; 102(3):280-7. PubMed ID: 24676648
[TBL] [Abstract][Full Text] [Related]
9. High-Throughput NanoBiT-Based Screening for Inhibitors of HIV-1 Vpu and Host BST-2 Protein Interaction.
Li B; Dong X; Zhang W; Chen T; Yu B; Zhao W; Yang Y; Wang X; Hu Q; Wang X
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502213
[TBL] [Abstract][Full Text] [Related]
10. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
11. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface.
Dubé M; Paquay C; Roy BB; Bego MG; Mercier J; Cohen EA
Traffic; 2011 Dec; 12(12):1714-29. PubMed ID: 21902775
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions.
Skasko M; Wang Y; Tian Y; Tokarev A; Munguia J; Ruiz A; Stephens EB; Opella SJ; Guatelli J
J Biol Chem; 2012 Jan; 287(1):58-67. PubMed ID: 22072710
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
15. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
Arias JF; Iwabu Y; Tokunaga K
Curr HIV Res; 2012 Jun; 10(4):283-91. PubMed ID: 22524176
[TBL] [Abstract][Full Text] [Related]
16. Expression, purification and characterization of a full-length recombinant HIV-1 Vpu from inclusion bodies.
Njengele Z; Kleynhans R; Sayed Y; Mosebi S
Protein Expr Purif; 2016 Dec; 128():109-14. PubMed ID: 27590917
[TBL] [Abstract][Full Text] [Related]
17. A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from antagonizing the host restriction factor BST-2.
Mi Z; Ding J; Zhang Q; Zhao J; Ma L; Yu H; Liu Z; Shan G; Li X; Zhou J; Wei T; Zhang L; Guo F; Liang C; Cen S
Sci Rep; 2015 Dec; 5():18499. PubMed ID: 26669976
[TBL] [Abstract][Full Text] [Related]
18. Correlation of biological activity with computationally derived structural features from transmembrane hetero-dimers of HIV-1 Vpu with host factors.
Li LH; Fischer WB
Biochim Biophys Acta; 2014 Apr; 1838(4):1104-12. PubMed ID: 24036078
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses.
Prévost J; Pickering S; Mumby MJ; Medjahed H; Gendron-Lepage G; Delgado GG; Dirk BS; Dikeakos JD; Stürzel CM; Sauter D; Kirchhoff F; Bibollet-Ruche F; Hahn BH; Dubé M; Kaufmann DE; Neil SJD; Finzi A; Richard J
mBio; 2019 Jun; 10(3):. PubMed ID: 31213558
[TBL] [Abstract][Full Text] [Related]
20. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility.
Kobayashi T; Ode H; Yoshida T; Sato K; Gee P; Yamamoto SP; Ebina H; Strebel K; Sato H; Koyanagi Y
J Virol; 2011 Jan; 85(2):932-45. PubMed ID: 21068238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
